Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.15)
# 3,272
Out of 4,479 analysts
9
Total ratings
25%
Success rate
-36.85%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $45.54 | +5.40% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $4 → $3 | $0.89 | +237.08% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $59.02 | +32.16% | 1 | Aug 3, 2022 | |
| BNOX Bionomics | Initiates: Outperform | $17 | $0.71 | +2,302.83% | 1 | Jan 10, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | n/a | $12.16 | - | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | n/a | $2.06 | - | 1 | May 25, 2021 | |
| FNCH Finch Therapeutics Group | Initiates: Outperform | n/a | $1.37 | - | 1 | Apr 13, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $45.54
Upside: +5.40%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $4 → $3
Current: $0.89
Upside: +237.08%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $59.02
Upside: +32.16%
Bionomics
Jan 10, 2022
Initiates: Outperform
Price Target: $17
Current: $0.71
Upside: +2,302.83%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.16
Upside: -
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.06
Upside: -
Finch Therapeutics Group
Apr 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.37
Upside: -